OC&C advises De Agostini S.p.A. in Pharmaceutical CDMO deal with Aksìa

We’re pleased to congratulate De Agostini S.p.A. on agreeing to acquire Content Group, an Italian pharmaceutical CDMO, from Aksia. OC&C supported De Agostini S.p.A. with buy-side commercial due diligence.

Content Group is a European leader in the development and contract manufacturing of medical devices and pharmaceutical products in the ophthalmic and inhalation segments. The group consists of two legal entities: COC Farmaceutici, founded in 1990 and focusing on the production of medical devices, and Tubilux Pharma, who specialise in developing and producing pharmaceutical products.

Content Group’s business model extends from pharmaceutical and medical device research & development services, to manufacturing and packaging activities, meeting the needs of both large blue-chip multinationals and specialised players, leaders in their niches.

We look forward to seeing the continued success of De Agostini S.p.A., and Content Group.

OC&C and Private Equity

We’re a leading global strategy consultancy, with deep expertise in the pharma sector, working with both major global corporations and local champions. In private equity, we have commercially advised on more than 500 successful transactions over the last 5 years, encompassing sell-side and buy-side roles.

How we can help: 

• We provide commercial due diligence and vendor due diligence for transactions.
• We assist investors with accelerating or improving their portfolio companies’ performance.
• We help investors identify potential investment themes or assets to target.
• We can translate your investment thesis into an actionable 3-5 year value creation plan.

For more details on our experience in this space, please contact: